To explore characteristics among generalized myasthenia gravis (gMG) patients treated with standard of care (SOC) therapies.

Generalized myasthenia gravis (gMG) is a rare, autoimmune condition affecting the neuromuscular junction. As the MG treatment landscape has evolved to include novel, targeted immunotherapies, clinicians have the option to tailor treatment based on clinical characteristics to potentially improve outcomes and patient satisfaction.

Data came from a US-based survey of gMG patients conducted in October 2024 and included those prescribed SOC at time of survey. Patients self-reported demographics, clinical characteristics current treatment satisfaction and disease status. Descriptive statistics are presented.

Overall, 157 patients were included: mean (standard deviation; SD) age of 50 (14) years, 89% female, and 39 (16) years at diagnosis. Respectively, 38.9% were Myasthenia Gravis Foundation of America class II, 50.3% class III and (10.8%) class IV. Mean (SD) myasthenia gravis – activities of daily living (MG-ADL) score was 8.5 (3.4) and 86.6% had a score of < 5. The most frequently reported symptoms were physical fatigue (91.7%), weakness in arms (72.0%) and weakness in legs (72.0%). In the 12 months prior to survey, 59.9% reported experiencing at least one symptom exacerbation, 36.3% reported at least one hospitalization and 14.0% reported a myasthenic crisis. Mean (SD) time on current treatment was 2.9 (4.2) years. Overall, 32.5% of patients reported being either dissatisfied or very dissatisfied with their current treatment and 28.7% described their condition/symptoms as worse than 12 months ago.

Self-reported high MG-ADL scores, frequent clinical events and persisting symptoms in this patient population with gMG highlights the existing unmet need in patients treated with SOC. These findings suggest there exists a high proportion of gMG patients for whom advanced therapies should be considered to provide sustained symptom control and reduce clinical events.